1. Scrip

Zogenix’s Fintepla Reduces Drop Seizure Rates, But Is It Enough?

 
• By Mandy Jackson

Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex. 

Red dart arrow hitting in the target center of dartboard with modern city and sunset background. Target business, achieve and victory concept .
Fintepla reduced monthly drop seizures in Lennox-Gastaut syndrome

Zogenix Inc. has struggled to bring Fintepla (ZX008, fenfluramine oral solution) to market for patients with rare seizure disorders, but on the heels of a US Food and Drug Administration approval decision expected by 25 March for the treatment of Dravet syndrome, the company may also seek approval in Lennox-Gastaut syndrome (LGS) based on new top-line Phase III results.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from R&D